Table 3.

Details of NIH-recommended antiviral therapeutics drug for non-hospitalized patients with mild-moderate COVID-19 (including Omicron variant) at high risk of progression to severe disease. The details on the name of the drug, mode of action, doses, route with the start of symptom onset, age, and efficacy.

S. No.	Name of the drug	Mode of action	Doses	Route	Symptom onset	Age	Efficacy
1	Paxlovid (Ritonavir-Boosted Nirmatrelvir)	n = protease inhibitor, halts viral replication of all known coronaviruses r = CYP 3A4 inhibitor (boosting agent)	300 mg	Orally	Start after 5th day	Age above 12 years	88%
2	Remdesivir	Prodrug of adenosine analog ends viral RNA transcription	200 mg (day 1) 100 mg (2nd and 3rd days)	Orally	Start after 7th day	Age above 12 years	87%
3	Bebtelovimab	Monoclonal antibody	175 mg	IV infusion	Start after 10th day	Age above 12 years	–
4	Molnupiravir	The prodrug of ß-D-N4hydroxycytidine (NHC) induces lethal RNA viral mutagenesis	800 mg	Orally	Start after 5th day	Age above 18 years	30%
5	Sotrovimab	Monoclonal antibody	500 mg	IV infusion	Start after 10th day	Age above 12 years	85%